Summary by Moomoo AI
On July 19, 2024, Allarity Therapeutics, Inc. received a Wells Notice from the U.S. Securities and Exchange Commission (SEC) in connection with an ongoing SEC investigation. The notice pertains to the company's disclosures about its interactions with the FDA over its New Drug Application (NDA) for Dovitinib, submitted in 2021. The SEC's preliminary determination suggests a potential enforcement action for alleged violations of federal securities laws, related to conduct from or before the 2022 fiscal year. Allarity Therapeutics, which is listed on the Nasdaq under the symbol ALLR, and three of its former officers have also received Wells Notices for the same issues. The company, asserting that its actions were appropriate, plans to respond formally to the SEC and is currently cooperating with the investigation.
